Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD Patients
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This is a phase 2b, multicenter, prospective, randomized, double-blind, placebo-controlled,
crossover study in symptomatic celiac disease patients attempting a GFD for at least one year
prior to screening.
Phase:
Phase 2
Details
Lead Sponsor:
Immunogenics, LLC
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)